Medical device maker Guidant Corp. said Wednesday it still believed its acquisition by Johnson & Johnson makes strategic sense, the day after the company's stock plummeted when Robert J. Daretta, the CFO of J&J, said it was considering alternatives to the $25.4 billion deal. Daretta's statement was the first public indication the acquisition may be in trouble, rather than just delayed. According to documents filed with the SEC, if J&J walked away from the deal, it would have to pay Guidant $700 million.
October 20, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Company DescriptionA prominent boutique AV rated Education Law firm located in Westbury, New York. Our firm specializes in education law, sp...
Seeking motivated and skilled litigation attorney to join our dynamic defense litigation firm. Role Involves:Conducting thorough research.Ha...
DEPUTY PORT ATTORNEY III Oakland, CA Salary: $17,294 - $21,419/month, 37.5-hr work week Your Port. Your Community. Your Career. Whe...